[{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-3287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KM602","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bireociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XZP-3621","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XZP-3287","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XZP-3621","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-5955","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-3621","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-5610","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-6019","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XZB-0004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"14-C XZP-3621","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-3621","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XZP-3621","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-3287","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XZP-3287","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"14-C XZP-3287","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XZB-0004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KM501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xuanzhu Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Xuanzhu Biopharm","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"KM-501","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xuanzhu Biopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharm \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Xuanzhu Biopharm \/ Innovent Biologics"}]
Find Clinical Drug Pipeline Developments & Deals by Xuanzhu Biopharm
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
